Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

So far, advanced therapy developers have been focusing on partnerships with specific hospitals for collecting patient cellular materials, and there are long-term concerns over the ability for the ...

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

DNA (deoxyribonucleic acid) is the nucleic acid polymer that forms the genetic code for a cell or virus. Most DNA molecules consist of two polymers (double-stranded) of four nucleotides that each ...